Exenatide vs SNAP-8
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- SNAP-8 is a synthetic octapeptide cosmetic ingredient that reduces the depth of expression lines and wrinkles by competitively inhibiting the SNARE complex involved in acetylcholine release at neuromuscular junctions, providing a topical 'Botox-like' effect.
- Half-Life
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- N/A — topical application; local effect duration depends on formulation
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 5 mcg, titrate to 10 mcg
- 3–10% concentration in formulation
- Frequency
- Twice daily
- 1–2x daily
- Key Benefits
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Reduces depth of dynamic expression wrinkles
- Smooths forehead lines, crow's feet, glabellar lines
- Non-invasive topical Botox alternative
- Can be incorporated into serums, creams, eye contour products
- Reduces muscle contraction without paralysis
- Improves skin texture and firmness over time
- Complements other anti-aging peptides (Argireline, Matrixyl)
- Side Effects
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Generally excellent tolerability
- Rare: mild redness in sensitive individuals
- Not suitable for injection (topical use only)
- Stacks With
- —
- —